Open original FDA record ↗Recall record
- FDA identifier
- Z-1752-2010
- Company in FDA record
- DiaDexus, Inc
- FDA classification date
- Jun 3, 2010
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 20, 2026
- Recall classification
- Unknown — no matched enforcement classification
Reason stated in the source
Inaccurate results-- some samples may return with falsely elevated results potentially as a result of an interfering substance. Some patients may be subjected to additional lifestyle changes or intensified pharmaceutical therapy; such as statins, as a result of the falsely elevated result.
Source facts
- Action
- Notification letter issued to consignees on 10/29/2009. Customers were instructed to not report PLAC test results for samples that are greater than 360 ng/mL, and pursue confirmatory testing by contacting DiaDexus. Customers with questions please call the company technical support line toll free at 1-877-752-2837 for assistance. UPDATE: On April 30, the firm suspended marketing of the PLAC TIA method, as the limited range no longer covered the clinical data/reference range data cited in the product insert. The firm sent out a letter notifying customers on May 10, 2010. The firm set up a sample send out program, so that customers can send samples to labs running the ELISA method PLAC test. Arrangements were made so that labs could be enabled to run a CLIA complex assay, for customer credit programs for un-used products, and a fax back response form for response tracking.
- Initiated
- 2009-10-29
- Root cause
- Other
- Terminated
- 2011-01-26
- Distribution
- Product was distributed to 123 consignees throughout the US.
- Recall number
- Z-1752-2010
- Recall status
- Terminated
- CDRH record ID
- 86706
- FDA classified
- 2010-06-03
- Recall event number
- 53856